Clause 9 covers the relationship between the investigational medicinal product identifier, the investigational package component identifier and the PhPID. The investigational identifiers are assigned to a product used in a clinical trial, supplementary to any identifier the regulator or the sponsor already uses. The clause asks how those identifiers associate with the composition-level identifier. The public contents give the title but not the body. The association rules and the direction of the relationship are not stated in the text we hold. The terms clause gives the definitions that make the question possible: an investigational medicinal product is one under test in a trial, or used there as a comparator, and that includes a marketed product used outside its authorisation, for an unapproved indication, or to learn more about its authorised form. That definition is why the clause matters: the same product can be both marketed and investigational, and the two identities have to be linked.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.